Related Experiment Video
Updated: Jul 13, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors
1Section of Andrology & Male Infertility, Department of Urology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA. whellst@tulane.edu
International Journal of Clinical Practice
|July 28, 2007
Summary
Phosphodiesterase type-5 (PDE5) inhibitors are safe and well-tolerated for treating erectile dysfunction (ED). Clinical data show no atypical safety issues, even in patients with comorbidities, supporting their established guidelines for use.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Urology
Background:
- Phosphodiesterase type-5 (PDE5) inhibitors have revolutionized erectile dysfunction (ED) treatment.
- Initial concerns regarding cardiovascular (CV) safety due to vasodilatory effects were raised.
Purpose of the Study:
- To review the safety and tolerability of PDE5 inhibitors in men with ED.
- To assess cardiovascular safety and adverse events associated with PDE5 inhibitor use.
Main Methods:
- Electronic literature review of existing data.
- Evaluation of clinical trial and postmarketing surveillance data.
Main Results:
- No atypical cardiovascular safety issues were identified in clinical trials.
- PDE5 inhibitors demonstrate a favorable safety and tolerability profile.
- No causal link established between PDE5 inhibitors and non-arteritic anterior ischaemic optic neuropathy (NAION).
Conclusions:
- PDE5 inhibitors are confirmed safe and well-tolerated for ED treatment.
- Established guidelines support the safe use of PDE5 inhibitors, even in patients with comorbidities.
- Data confirm safety in patients with endothelial dysfunction-associated comorbidities.
Related Concept Videos
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:17Male Sexual Response: Erection & Ejaculation
Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...